沈迎,张奇,张瑞岩,沈卫峰

• 1:上海交通大学医学院附属瑞金医院心脏科

摘要(Abstract)：

<正>在发达国家,新诊断的心力衰竭患者逐年增加。其中,左心室功能[左心室射血分数(LVEF)]正常或减低者各占一半[1]。随着我国经济飞速发展,社会老龄化逐渐形成,冠状动脉粥样硬化性心脏病(冠心病)发生率呈明显增高趋势。冠状动脉血运重建技术[包括经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)]的改进和新药物的临床应用,使许多高危复杂冠心病患者的急性期死亡率显著降低,但仍有相当比例患者残留左心室功能不全,甚至发展成严重的心力衰竭。不仅明显增加冠心病合并左心室功能不全患者的绝对数量,也影响着冠心病患者

关键词(KeyWords)： 左心室功能;左心室射血分数;血运重建;冠心病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 沈迎,张奇,张瑞岩,沈卫峰

参考文献(References)：

• [1]Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA Guideline for the Management of Heart Failure:Executive summary:A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation,2013,128:1810-1852.
• [2]Park DW,Kim YH,Song HG,et al.Long-term comparison of drugeluting stents and coronary artery bypass grafting for multivessel coronary revascularization:5-year outcomes from the Asia Medical Center-multivessel revascularization registry.J Am Coll Cardiol,2011,57:128-137.
• [3]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention.J Am Coll Cardiol,2011,58:e44-122.中国介入心脏病学杂志2014年3月第22卷第3期Chin J Intervent Cardiol,March 2014,Vol 22,No.3·187·
• [4]He J,Ogden LG,Bazzano LA,et al.Risk factors for congestive heart failure in US men and women:NHANES I epidemiologic follow-up study.Arch Intern Med,2001,161:996-1002.
• [5]Mohammad A,Mahy IR,Norton MY,et al.Prevalence of hibernating myocardium in patients with severely impaired ischemic left ventricle.Heart,1998,80:559-564.
• [6]张奇,沈卫峰,张建盛,等.左心室功能不全患者冠状动脉内支架术疗效及预后研究.临床心血管病杂志,2003,12:205-208.
• [7]Velazquez EJ,Lee KL,Deja MA,et al.Coronary-artery bypass surgery in patients with left ventricular dysfunction.N Engl J Med,2011,364:1607-1616.
• [8]Kunadian V,Zaman A,Qiu W.Revascularization among patients with severe left ventricular dysfunction:a meta-analysis of observational studies.Eur J Heart Fail,2011,13:773-784.
• [9]Tsuyuki RT,Shrive FM,Galbraith PD,et al..Revascularization in patients with heart failure.CMAJ,2006,175:361-365.
• [10]Cleland JG,Calvert M,Freemantle N,et al.The Heart Failure Revascularization Trial(HEART).Eur J Heart Fail,2011,12:227-233.
• [11]Gioia G,Malthai W,Gillin K,et al.Revascularization in severe left ventricular dysfunction:outcome comparison of drug-eluting stent implantation versus coronary artery bypass grafting.Catheter Cardiovasc Interv,2007,70:26-33.
• [12]Marsico F,Morebghi E,Parenti DZ,et al.Immediate and late results of coronary angioplasty in patients with severe left ventricular dysfunction.Ital Heart J,2003,4:838-842.
• [13]Biondi-Zoccai G,Sheiban I,Moretti G,et al.Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease:insights from a multicenter registry of 975 patients.Clin Res Cardiol,2011,100:403-411.
• [14]Morice MC,Serruys PW,Kappetein AP,et al.Outcome in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery(SYNTAX)trial.Circulation,2010,121:2645-2653.
• [15]Kappetein AP,Feldman TE,Mack MJ,et al.Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three vessel disease:3-year follow-up of the SYNTAX trial.Eur Heart J,2011,32:2125-2134.
• [16]Kunadian V,Pugh A,Zaman AG,et al.Percutaneous coronary intervention among patients with left ventricular systolic dysfunction:a review and meta-analysis.Coron Artery Dis,2012,23:469-479.
• [17]Sedlis SP,Ramanathan KB,Morrison DA,et al.Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fraction,unstable angina pectoris,and risk factors for adverse outcomes with bypass(the AWESOME Randomized Trial and Regstry).Am J Cardiol,2004,94:118-120.
• [18]Gao Z,Xu B,Kirtane AJ,et al.Impact of depressed left ventricular function on outcomes in patients with three-vessel coronary disease undergoing percutaneous coronary intervention.Chin Med J,2013,126:609-614.
• [19]McMurray JJ,Adamopoulos S,Anker SD,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heartfailure2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology.Eur Heart J,2012,33:1787-1847.
• [20]中华医学会心血管病分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本).中华心血管病杂志,2012,40:271-277.
• [21]Wijns W,Kolh P,Danchin N,et al.Guidelines on myocardial revascularization.Eur Heart J,2010,31:2501-2555.
• [22]苗志林,曾定尹.药物涂层支架防治再狭窄的研究现状.中国介入心脏病学杂志,2003,11:48-51.
• [23]Voudris V,Kariofi llis P,Thomopoulou S,et al.Predictors for very late stent thrombosis after drug-eluting stent implantation in diabetic patients.Eurointervention,2009,4:485-491.
• [24]Kimura T,Morimoto T,Kozuma K,et al.Comparisons of baseline demographics,clinical presentation,and long-term outcome among patients with early,late,and very late stent thrombosis of sirolimuseluting stents:Observations from the Registry of Stent Thrombosis for Review and Reevaluation(RESTART).Circulation,2010,122:52-61.